292 related articles for article (PubMed ID: 33119110)
1. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
Shao C; Li G; Huang L; Pruitt S; Castellanos E; Frampton G; Carson KR; Snow T; Singal G; Fabrizio D; Alexander BM; Jin F; Zhou W
JAMA Netw Open; 2020 Oct; 3(10):e2025109. PubMed ID: 33119110
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
[TBL] [Abstract][Full Text] [Related]
3. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
[TBL] [Abstract][Full Text] [Related]
6. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
[TBL] [Abstract][Full Text] [Related]
7. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
8. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
[TBL] [Abstract][Full Text] [Related]
9. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
[TBL] [Abstract][Full Text] [Related]
10. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
[TBL] [Abstract][Full Text] [Related]
11. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
12. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Lee KW; Van Cutsem E; Bang YJ; Fuchs CS; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Chao J; Wainberg ZA; Cao ZA; Aurora-Garg D; Kobie J; Cristescu R; Bhagia P; Shah S; Tabernero J; Shitara K; Wyrwicz L
Clin Cancer Res; 2022 Aug; 28(16):3489-3498. PubMed ID: 35657979
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
14. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
15. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.
Scobie MR; Zhou KI; Ahmed S; Kelley MJ
JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430
[TBL] [Abstract][Full Text] [Related]
16. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
17. Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.
Kim H; Kim H; Kim R; Jo H; Kim HR; Hong J; Park JO; Park YS; Kim ST
Technol Cancer Res Treat; 2021; 20():15330338211062324. PubMed ID: 34855561
[No Abstract] [Full Text] [Related]
18. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
[TBL] [Abstract][Full Text] [Related]
19. Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.
Araujo DV; Wang A; Torti D; Leon A; Marsh K; McCarthy A; Berman H; Spreafico A; Hansen AR; Razak AA; Bedard PL; Wang L; Plackmann E; Chow H; Bao H; Wu X; Pugh TJ; Siu LL
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34056539
[TBL] [Abstract][Full Text] [Related]
20. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
